TG Therapeutics said it is working to develop a subcutaneous (under-the-skin) version of relapsing MS therapy Briumvi.
Switching therapies is a common part of multiple sclerosis management and may be considered for several reasons.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback